Dr. Reddy's Gets FDA Warning Letter, To Fully Comply With CGMP Quality Standards

(RTTNews) - Dr. Reddy's Laboratories (DRREDDY, 500124, RDY) issued a statement acknowledging that it has received a warning letter issued by the US FDA relating to its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh.

This action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015, respectively.

Dr. Reddy's CEO, G V Prasad commented, "We take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards across all of our facilities. We will respond with a comprehensive plan to address these observations within the stipulated time-frame of 15 days."

G V Prasad added that the company would continue to actively engage with the agency to resolve these issues and have also embarked on an initiative to revamp the company's quality systems and processes, as an organization-wide priority.